Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

CTMX

CytomX Therapeutics (CTMX)

CytomX Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CTMX
FechaHoraFuenteTítuloSímboloCompañía
01/03/202215:15GlobeNewswire Inc.CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
28/02/202207:00GlobeNewswire Inc.CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
22/02/202207:00GlobeNewswire Inc.CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022NASDAQ:CTMXCytomX Therapeutics Inc
16/02/202207:00GlobeNewswire Inc.CytomX Therapeutics Announces New Employment Inducement GrantsNASDAQ:CTMXCytomX Therapeutics Inc
14/02/202216:08Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CTMXCytomX Therapeutics Inc
14/02/202215:28Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CTMXCytomX Therapeutics Inc
07/02/202208:00GlobeNewswire Inc.CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating OfficerNASDAQ:CTMXCytomX Therapeutics Inc
04/02/202215:52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CTMXCytomX Therapeutics Inc
19/01/202207:00GlobeNewswire Inc.CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid TumorsNASDAQ:CTMXCytomX Therapeutics Inc
05/01/202207:00GlobeNewswire Inc.CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
03/01/202215:35Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CTMXCytomX Therapeutics Inc
29/12/202110:19Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:CTMXCytomX Therapeutics Inc
27/12/202105:56TipRanksIs CytomX Stock a Buy Following Disappointing Cancer Therapy Results? Analyst Weighs InNASDAQ:CTMXCytomX Therapeutics Inc
21/12/202101:11TipRanksMizuho Securities Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)NASDAQ:CTMXCytomX Therapeutics Inc
20/12/202115:05GlobeNewswire Inc.CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71NASDAQ:CTMXCytomX Therapeutics Inc
11/11/202107:00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming November Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
04/11/202115:15GlobeNewswire Inc.CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
04/11/202115:10Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CTMXCytomX Therapeutics Inc
01/11/202107:00GlobeNewswire Inc.CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Platform at Society for Immunotherapy of Cancer Annual MeetingNASDAQ:CTMXCytomX Therapeutics Inc
28/10/202107:00GlobeNewswire Inc.CytomX Therapeutics to Announce Third Quarter 2021 Financial Results on November 4, 2021NASDAQ:CTMXCytomX Therapeutics Inc
04/10/202107:00GlobeNewswire Inc.CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of DirectorsNASDAQ:CTMXCytomX Therapeutics Inc
07/09/202107:00GlobeNewswire Inc.CytomX Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
19/08/202105:06Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CTMXCytomX Therapeutics Inc
05/08/202116:06Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:CTMXCytomX Therapeutics Inc
05/08/202115:15GlobeNewswire Inc.CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business UpdateNASDAQ:CTMXCytomX Therapeutics Inc
04/08/202107:00GlobeNewswire Inc.CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1)NASDAQ:CTMXCytomX Therapeutics Inc
02/08/202107:00GlobeNewswire Inc.CytomX Therapeutics to Present at Upcoming August Investor ConferencesNASDAQ:CTMXCytomX Therapeutics Inc
29/07/202107:00GlobeNewswire Inc.CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021NASDAQ:CTMXCytomX Therapeutics Inc
21/06/202107:00GlobeNewswire Inc.CytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer ResearchNASDAQ:CTMXCytomX Therapeutics Inc
27/05/202107:00GlobeNewswire Inc.CytomX Therapeutics to Present at Jefferies Virtual Healthcare ConferenceNASDAQ:CTMXCytomX Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CTMX

Su Consulta Reciente

Delayed Upgrade Clock